Stockscreener 앱 받기
2.04
0.97%
-0.02
Protalix BioTherapeutics Inc. 주식(PLX)의 최신 뉴스
Aug Action: Will Protalix BioTherapeutics Inc benefit from government policy - baoquankhu1.vn
Aug Selloffs: What is Protalix BioTherapeutics Inc. s 5 year growth outlookJuly 2025 Earnings & Daily Profit Focused Screening - bollywoodhelpline.com
Protalix, Secarna in agreement to develop rare kidney disorder therapies - MSN
Why Protalix BioTherapeutics Inc. (DE) stock remains stableJuly 2025 Technicals & Risk Adjusted Swing Trade Ideas - Улправда
Will Protalix BioTherapeutics Inc. (PBDA) stock outperform Dow JonesJuly 2025 Big Picture & Short-Term High Return Strategies - Улправда
Can Protalix BioTherapeutics Inc. stock hit analyst price targetsJuly 2025 WrapUp & Reliable Intraday Trade Plans - Улправда
Will Protalix BioTherapeutics Inc. stock gain from strong economyStop Loss & Target Return Focused Stock Picks - Улправда
Is Protalix BioTherapeutics Inc. (DE) stock dividend growth reliableMarket Performance Recap & High Conviction Trade Alerts - Улправда
Is Protalix BioTherapeutics Inc. (PBDA) stock a safe buy pre earningsJuly 2025 Short Interest & Fast Moving Trade Plans - Улправда
Will Protalix BioTherapeutics Inc. (PBDA) stock sustain dividend payoutsPortfolio Value Report & Daily Chart Pattern Signal Reports - Улправда
Is Protalix BioTherapeutics Inc. (PBDA) stock among top earnings playsWeekly Investment Report & Stepwise Trade Signal Implementation - Улправда
What technical charts say about Protalix BioTherapeutics Inc. stock2025 Support & Resistance & Risk Managed Investment Signals - Улправда
How Low Can Protalix BioTherapeutics Stock Really Go? - Trefis
Why Protalix BioTherapeutics Inc. (DE) stock benefits from AI revolution2026 world cup usa national team qualification young talents pressing system expert forecast preview - Улправда
Protalix outlines 2026 strategy with focus on uncontrolled gout therapy By Investing.com - Investing.com Nigeria
PLX: Secarna’s antisense oligonucleotide discovery collaboration - MSN
Protalix BioTherapeutics CEO outlines 2026 priorities, highlights progress across clinical pipeline - Proactive financial news
Protalix outlines 2026 strategy with focus on uncontrolled gout therapy - Investing.com
Protalix BioTherapeutics, Inc. Provides 2026 Strategic Update - TradingView — Track All Markets
Protalix BioTherapeutics Letter to Stockholders - Nasdaq
What’s Driving Mazda Limited Stock’s Recent Momentum Key TrendsSector Performance Drivers & Explosive Profit Growth - earlytimes.in
Market Fear: How strong is Protalix BioTherapeutics Inc DE stock earnings growthWeekly Trade Recap & Community Trade Idea Sharing - Bộ Nội Vụ
Protalix BioTherapeutics (AMEX: PLX)Related Research - intelligentinvestor.com.au
Protalix BioTherapeutics (NYSE:PLX) CEO Buys $101,360.00 in Stock - MarketBeat
Bashan Dror, Protalix BioTherapeutics CEO, buys $101k in shares By Investing.com - Investing.com Canada
Protalix BioTherapeutics (PLX) CEO and director reports 56,000-share stock purchase - Stock Titan
PLX: Secarna's Antisense Oligonucleotide Discovery Collaboration - Research Tree
PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration - Zacks Small Cap Research
How Protalix BioTherapeutics Inc. (DE) stock reacts to weak economyJuly 2025 Opening Moves & Community Verified Trade Alerts - Улправда
Will Protalix BioTherapeutics Inc. (DE) stock outperform Dow JonesWeekly Gains Summary & Entry Point Strategy Guides - DonanımHaber
Can Protalix BioTherapeutics Inc. stock beat analyst upgradesWeekly Gains Summary & Verified Entry Point Detection - Улправда
Institution Moves: Is Protalix BioTherapeutics Inc. stock a contrarian buyBond Market & Community Verified Trade Signals - Улправда
Is Protalix BioTherapeutics Inc. (DE) stock a buy before new product rolloutJuly 2025 Institutional & Reliable Price Breakout Alerts - DonanımHaber
Sentiment Review: Is Protalix BioTherapeutics Inc. stock attractive for hedge fundsJuly 2025 Volume & High Win Rate Trade Tips - Улправда
Protalix BioTherapeutics (NYSE:PLX) Trading Up 2.3%Still a Buy? - MarketBeat
Protalix BioTherapeutics (NYSE:PLX) Trading Up 2.3% – Still a Buy? - Defense World
Breakout Zone: How Protalix BioTherapeutics Inc. (DE) stock reacts to weak economyJuly 2025 Technicals & AI Forecast for Swing Trade Picks - Улправда
Is Protalix BioTherapeutics Inc. stock a contrarian buy2025 Big Picture & Technical Pattern Based Buy Signals - Улправда
Protalix and Secarna partner to develop rare kidney disease treatments By Investing.com - Investing.com South Africa
Protalix BioTherapeutics partners with Secarna Pharmaceuticals on rare kidney disease drug development - Proactive financial news
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement - Finviz
Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics… - Proactive Investors
Protalix BioTherapeutics (PLX) Partners with Secarna for Kidney Disorder Treatments - GuruFocus
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter Into Collaboration and Option Agreement - 富途牛牛
Protalix Partners With Secarna to Jointly Develop Therapies for Rare Renal Indications - marketscreener.com
Protalix and Secarna partner to develop rare kidney disease treatments - Investing.com
4.73%
0.92%
자본화:
|
볼륨(24시간):